Neuronal nitric oxide synthase regulates basal microvascular tone in humans in vivo
Neuronal nitric oxide synthase regulates basal microvascular tone in humans in vivo
复制标题
DOI:
10.1161/circulationaha.107.744540
复制
发表时间:
2008-04-15
期刊:
影响因子:
37.8
通讯作者:
Shah, Ajay M.
中科院分区:
文献类型:
--
作者:
Seddon, Michael D.;Chowienczyk, Philip J.;Shah, Ajay M.
Background - Nitric oxide ( NO) has a pivotal role in the regulation of vascular tone and blood flow, with dysfunctional release contributing to disease pathophysiology. These effects have been attributed to NO production by the endothelial NO synthase ( eNOS); however, recent evidence suggests that a neuronal NO synthase ( nNOS) may also be expressed in arterial vessels.Methods and Results - We undertook a first-in- humans investigation of the role of nNOS in the local regulation of vascular blood flow in healthy subjects. Brachial artery infusion of the nNOS- specific inhibitor S- methyl- L- thiocitrulline ( SMTC, 0.025 mu mol/ min to 0.2 mu mol/ min) caused a dose- dependent reduction in basal flow, with a 30.1 +/- 3.8% decrease at the highest dose ( n = 10; mean +/- SE; P < 0.01). The effect of SMTC was abolished by coinfusion of the NO synthase substrate L- arginine but was unaffected by D- arginine. A similar reduction in basal flow with the nonselective NO synthase inhibitor N-G- monomethyl-L-arginine ( L- NMMA; 37.4 +/- 3.1%, n = 10) required a 20- fold higher dose of 4 mu mol/ min. At doses that produced comparable reductions in basal flow, only L- NMMA ( 4 mu mol/ min) and not SMTC ( 0.2 mu mol/ min) inhibited acetylcholine- induced vasodilation; however, both SMTC and L- NMMA inhibited the forearm vasodilator response to mental stress.Conclusions - Basal forearm blood flow in humans is regulated by nNOS- derived NO, in contrast to the acetylcholinestimulated increase in blood flow, which, as shown previously, is mediated primarily by eNOS. These data indicate that vascular nNOS has a distinct local role in the physiological regulation of human microvascular tone in vivo.